Edition:
United Kingdom

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

12.01USD
20 Apr 2018
Change (% chg)

$1.82 (+17.86%)
Prev Close
$10.19
Open
$10.19
Day's High
$14.68
Day's Low
$9.90
Volume
1,103,678
Avg. Vol
124,250
52-wk High
$14.99
52-wk Low
$2.69

Select another date:

Fri, Apr 20 2018

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-Biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals

* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION

BRIEF-Dicerna Pharma Files ‍Prospectus Related To Offering

* DICERNA PHARMACEUTICALS INC FILES ‍PROSPECTUS RELATED TO OFFERING UP TO 24.5 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING​ Source text: (http://bit.ly/2FKmcfn) Further company coverage:

BRIEF-Dicerna Reports Qtrly Loss Per Share Of $0.90

* DICERNA REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals

* ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017 Source text: (http://bit.ly/2Ac7p5t) Further company coverage:

BRIEF-RA Capital Management LLC Reports 9.9 Pct Stake In Dicerna Pharmaceuticals

* RA CAPITAL MANAGEMENT LLC REPORTS 9.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 18 - SEC FILING

BRIEF-Bain Capital Life Sciences Fund Reports 15.7 Percent Stake In Dicerna Pharmaceuticals

* BAIN CAPITAL LIFE SCIENCES FUND L.P. REPORTS 15.7 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON DEC 18 - SEC FILING

Select another date: